Quick answers
- What is Vasopressin (vasopressin, unspecified) used for?
- The FDA-approved label (Vasostrict, Par Health USA, LLC, April 21, 2026) says: “Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Vasopressin (vasopressin, unspecified) have a boxed warning?
- No. None of the 9 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Vasopressin (vasopressin, unspecified)?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Vasopressin (vasopressin, unspecified) been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started January 11, 2024 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Vasopressin (vasopressin, unspecified)?
- 5 companies list prescription products of Vasopressin (vasopressin, unspecified) in the FDA NDC Directory, including Par Health USA, LLC, HF Acquisition Co LLC, DBA HealthFirst and Medical Purchasing Solutions, LLC.
What Vasopressin (vasopressin, unspecified) is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
— FDA label: Vasostrict, Par Health USA, LLC, effective April 21, 2026. Read the full label on DailyMed →
The FDA has 9 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 9 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Injection |
|---|---|
| Route | Intravenous |
| Prescription products | 11 in the FDA NDC Directory |
| Brand names | Vasostrict |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Par Health USA, LLC5 products
- HF Acquisition Co LLC, DBA HealthFirst3 products
- Medical Purchasing Solutions, LLC2 products
- Dr. Reddy's Laboratories Inc.1 product
- Medical Purchasin Solutions, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA204485 VASOSTRICT | Ph Health | April 17, 2014 | 14, latest April 12, 2023 2023: Manufacturing (CMC) · 2022: Labeling · 2022: Labeling |
Generic approvals (2)
- ANDA214314Eugia Pharma · August 15, 2022
- ANDA213988DR Reddys · May 8, 2024
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 11, 2024 · Class II · Ongoing · D-0232-2024
Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit.
Vasostrict (vasopressin in 5% Dextrose) Injection, 20 units per 100 mL (0.2 units per mL), 100 mL x 10 Single Dose Vials per carton, Ready to Use, For Intravenous Infusion, Rx Only, Distributed by: Par Pharmaceutical, Ch — Par Sterile Products LLC
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Vasostrict, Par Health USA, LLC, effective April 21, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →